Clear Street’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.65M Buy
382,440
+28,392
+8% +$301K ﹤0.01% 317
2026
Q1
$1.3M Buy
354,048
+28,075
+9% +$293K 0.01% 305
2025
Q4
$996K Buy
325,973
+116,407
+56% +$1.2M ﹤0.01% 294
2025
Q3
$2.15M Buy
209,566
+96,951
+86% +$995K 0.01% 170
2025
Q2
$1.15M Buy
+112,615
New +$1.14M ﹤0.01% 114

Other funds holding DMAA

Clear Street's DMAA Position: Q2 2026 in Review

Clear Street increased its Drugs Made In America Acquisition Corp (DMAA) stake by 8% in Q2 2026, buying an estimated $301K and bringing the position to 382,440 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Clear Street first reported a position in DMAA in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.15M in Q3 2025. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Clear Street held 382,440 shares of Drugs Made In America Acquisition Corp worth $1.65M as of Q2 2026.
  • Clear Street bought 28,392 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $301K.
  • Drugs Made In America Acquisition Corp made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #317 holding.
  • Clear Street first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and has held it in 5 quarters since.
  • Clear Street's Drugs Made In America Acquisition Corp position peaked at $2.15M in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.